Capecitabine, Oxaliplatin, Pembrolizumab, and Trastuzumab
About
Membership operator: AND
Therapies: 4
Therapies
Capecitabine (tx:ncit:C1794)
Oxaliplatin (tx:ncit:C1181)
Pembrolizumab (tx:ncit:C106432)
Trastuzumab (tx:ncit:C1647)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | HER2-positive, PD-L1 (CPS) >= 1 | Adenocarcinoma of the Gastroesophageal Junction | Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab |